TRML — Tourmaline Bio Income Statement
0.000.00%
- $329.81m
- $36.76m
- 55
- 42
- 14
- 30
Annual income statement for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 18.4 | 22.7 | 47.5 | 76.5 | 45.4 |
Operating Profit | -18.4 | -22.7 | -47.5 | -76.5 | -45.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.2 | -22.7 | -47.8 | -73.9 | -42.1 |
Net Income After Taxes | -18.2 | -22.7 | -47.8 | -73.9 | -42.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.2 | -22.7 | -47.8 | -73.9 | -42.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.2 | -22.7 | -47.8 | -73.9 | -42.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.4 | -5.51 | -11.7 | -17.9 | -8.87 |
Dividends per Share | |||||
Special Dividends per Share |